Orchard Therapeutics Plc (ORTX) Misses Q3 EPS by 14c

Orchard Therapeutics Plc (NASDAQ: ORTX) reported Q3 EPS of ($0.37), $0.14 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $5.78 million versus the consensus estimate of $4.41 million.

For earnings history and earnings-related data on Orchard Therapeutics Plc (ORTX) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Innovative Solutions & Support (ISSC) Tops Q3 EPS by 10c
• Range Impact, Inc. (RNGE) Reports Q2 Loss of $0.02